ACE and COVID-19: However, a large community-based study has shown that the use of angiotensin-converting enzyme inhibitor (ACEI) or (ARB) was not associated with COVID-19 − confirmed case rate.[6] The same study has also shown that neither ACEI nor ARB use rates were associated with COVID-19 death rates.